Alec Stranahan
Stock Analyst at B of A Securities
(0.70)
# 3,990
Out of 5,072 analysts
32
Total ratings
36%
Success rate
-27.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $218.95 | +16.46% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $4.62 | +51.52% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $17.38 | -30.96% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $3.13 | -68.05% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $6.95 | +0.72% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $25.03 | +67.80% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $9.41 | +165.67% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.88 | +485.11% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.23 | +169.06% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.40 | +525.00% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $77.58 | -29.11% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $33.41 | -82.04% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $218.95
Upside: +16.46%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $4.62
Upside: +51.52%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $17.38
Upside: -30.96%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $3.13
Upside: -68.05%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $6.95
Upside: +0.72%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $25.03
Upside: +67.80%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $9.41
Upside: +165.67%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.88
Upside: +485.11%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.23
Upside: +169.06%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.40
Upside: +525.00%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $77.58
Upside: -29.11%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $33.41
Upside: -82.04%